57614-92-3

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
4-(4-Piperidyl)-1-butanol is utilized as a key building block in the synthesis of various pharmaceuticals and agrochemicals for its versatile reactivity, contributing to the development of new and improved products in these fields.
Used in Fragrance and Flavor Industry:
In the fragrance and flavor industry, 4-(4-Piperidyl)-1-butanol is employed as a component in creating distinct scents and tastes, capitalizing on its unique chemical properties to enhance the sensory experience of consumer products.
Used as a Chiral Building Block:
4-(4-Piperidyl)-1-butanol is used as a chiral building block in the synthesis of optically active compounds, playing a crucial role in the production of enantiomerically pure substances that are essential in various chemical and biological applications.
Overall, the diverse applications of 4-(4-Piperidyl)-1-butanol across different industries highlight its importance and value as a chemical compound with a wide range of uses.

Upstream product

• 5264-15-3 4-(4-pyridinyl)butan-1-ol 
• 372195-85-2 4-butylpiperidine hydrochloride 

Downstream Products

• 142355-83-7 4-(1-tert-butoxycarbonylpiperidin-4-yl)-butan-1-ol 
• 1041756-57-3 [4-(4-aminobutyl)-1-piperidinyl](phenyl)methenone 
• 1296137-14-8 2-{4-[1-(phenylcarbonyl)piperidin-4-yl]butyl}-1H-isoindole-1,3(2H)-dione 
• 1360619-08-4 (2E)-N-[4-(1-benzoylpiperidin-4-yl)butyl]-3-{3-[(2S,3S,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)pyrrolidin-2-yl]phenyl}prop-2-enamide hydrochloride 
• 1041756-51-7 C₁₆H₂₃NO₂ 
• 1338213-12-9 (E)-1-(4-(1-benzoylpiperidin-4-yl)butyl)-2-cyano-3-(pyridin-4-yl)guanidine 
• 201034-98-2 tert-butyl 4-(4-aminobutyl)piperidine-1-carboxylate 
• 142355-81-5 tert-butyl 4-(4-bromobutyl)piperidine-1-carboxylate 

Relevant academic research and scientific papers

PIPERIDINE DERIVATIVES FOR USE IN THE TREATMENT OF PANCREATIC CANCER

The present invention relates to novel piperidine derivatives having better cell growth inhibitory activities toward cancer cell cultures and, more particularly, PANC-1 cancer cell cultures than FK866. Accordingly, the present invention relates to compoun

Radiolabeled Dibenzodiazepinone-Type Antagonists Give Evidence of Dualsteric Binding at the M2 Muscarinic Acetylcholine Receptor

The dualsteric ligand approach, aiming at ligands with improved subtype selectivity, has been increasingly applied to muscarinic receptors (MRs). In this article, we present the synthesis and characterization of a M2R subtype-preferring radiola

Platinum-Catalyzed, Terminal-Selective C(sp3)-H Oxidation of Aliphatic Amines

This Communication describes the terminal-selective, Pt-catalyzed C(sp3)-H oxidation of aliphatic amines without the requirement for directing groups. CuCl2 is employed as a stoichiometric oxidant, and the reactions proceed in high yield at Pt loadings as low as 1 mol%. These transformations are conducted in the presence of sulfuric acid, which reacts with the amine substrates in situ to form ammonium salts. We propose that protonation of the amine serves at least three important roles: (i) it renders the substrates soluble in the aqueous reaction medium; (ii) it limits binding of the amine nitrogen to Pt or Cu; and (iii) it electronically deactivates the C-H bonds proximal to the nitrogen center. We demonstrate that this strategy is effective for the terminal-selective C(sp3)-H oxidation of a variety of primary, secondary, and tertiary amines.

M2 Subtype preferring dibenzodiazepinone-type muscarinic receptor ligands: Effect of chemical homo-dimerization on orthosteric (and allosteric?) binding

A series of new dibenzodiazepinone-type muscarinic receptor ligands, including two homo-dimeric compounds, was prepared. Sixteen representative compounds were characterized in equilibrium binding studies with [3H]N-methylscopolamine ([3H]NMS) at the muscarinic receptor subtype M2, and seven selected compounds were additionally investigated at M1, M3, M4 and M5 with respect to receptor subtype selectivity. The side chain of the known M2 preferring muscarinic receptor antagonist DIBA was widely varied with respect to chain length and type of the basic group (amine, imidazole, guanidine and piperazine). Most of the structural changes were well tolerated with respect to muscarinic receptor binding, determined by displacement of [3H]NMS. Compounds investigated at all subtypes shared a similar selectivity profile, which can be summarized as M2 > M1 ≈ M4 > M3 ≈ M5 (46, 50, 57, 62-64) and M2 > M1 ≈ M4 > M3 > M5 (1, 58). The homo-dimeric dibenzodiazepinone derivatives UNSW-MK250 (63) and UNSW-MK262 (64) exhibited the highest M2 receptor affinities (pIC50 = 9.0 and 9.2, respectively). At the M2 receptor a steep curve slope of -2 was found for the dimeric ligand 63, which cannot be described according to the law of mass action, suggesting a more complex mechanism of binding. In addition to equilibrium binding studies, for selected ligands, we determined pEC50,diss, an estimate of affinity to the allosteric site of M2 receptors occupied with [3H]NMS. Compounds 58 and 62-64 were capable of retarding [3H]NMS dissociation by a factor >10 (Emax,diss >92%), with highest potency (pEC50,diss = 5.56) residing in the dimeric compound 64. As the monomeric counterpart of 64 was 100 times less potent (62: pEC50,diss = 3.59), these data suggest that chemical dimerization of dibenzodiazepinone-type M receptor ligands can enhance allosteric binding.

Synthesis of a C-iminoribofuranoside analog of the nicotinamide phosphoribosyltransferase (NAMPT) inhibitor FK866

FK866 (also named APO866 or WK175) is a potent NAMPT inhibitor being evaluated (Phase II) as a potential anticancer drug. The preparation of the C-iminoribofuranoside analog (2E)-N-[4-(1-benzoylpiperidin-4-yl)butyl]-3-{3- [(2S,3S,4R,5R)-3,4-dihydroxy-5-(h

Synthesis and biological evaluation of PEG-tirofiban conjugates

We have conjugated tirofiban, an antagonist of the GPIIb/IIIa integrin receptor, to PEG, and shown that these polymers effectively inhibit platelet aggregation. This inhibition decreased with the size of the polymer. Our goal was to develop new cryoprotec